Most recently, New Mexico passed the landmark Medical Psilocybin Act( SB 219) in early 2025. This law establishes a therapeutic psilocybin program allowing people with qualifying conditions access under supervision by licensed providers. In April 2025, New Mexico Governor Michelle Lujan Grisham signed the act into law. It will establish the third state-legal psilocybin access system in the U. S.
And that brings us back to Missouri and what is happening currently. After the initial proposal by Rep. Matt Overcast of HB 951, which would legalize and regulate psilocybin therapy for people with certain mental health conditions, the activity has shifted to more fleshed-out bills, committee approvals, pilot program designs, and concrete regulatory guidelines, though many hurdles remain.
Aside from Missouri, these states are the ones to watch for psilocybin reform in 2025. They all appear positioned either to pass full legalization, legal medical programs, or meaningful decriminalization in the near term:
● Arizona: SB 1555 would legalize a pharmaceutical version of synthetic psilocybin, pending FDA approval.
● Massachusetts: Multiple bills are moving to reduce penalties and decriminalize small amounts, although a 2024 ballot measure to legalize plant-based psychedelics( Question 4) failed.
● California: Advocates and legislators continue pushing to create a path for therapeutic legalization, though some earlier bills( like SB 58) have been vetoed.
● Louisiana, Virginia, Connecticut, Illinois, New York, Rhode Island, New Hampshire, and other states are drafting bills that range from decriminalization to regulated therapeutics. The scope and strength vary, especially in oversight, provider licensure, and public safety.
There are some key policy issues and hurdles in psilocybin reform. States legalizing psilocybin under supervision( like Oregon, Colorado, and New Mexico) still face questions about how many clinics, costs, access, and training for facilitators will work in practice. Additionally, and similarly to cannabis, the legalization of this substance is not in alignment with the FDA and the federal government. Some proposals depend on federal approval( such as synthetic psilocybin in Arizona) or risk clashing with the Schedule I status of many psychedelics. Also, while voters often favor reform, legislative bodies hesitate over liability, safety, and stigma. Failed measures show how ballot initiatives can be unpredictable.
Nonetheless, it will be interesting to see how this plays out for the Show-Me State and how it will impact both public opinion and the established legalized cannabis industry.
Notice: Please note that any of the“ Acts,”“ Motions” or“ Bills”( HB) and( SB) mentioned were in motion at the time of this writing and are subject to future change.
Important Disclaimer: Psilocybin( mushrooms) and other such psychedelic substances are currently Schedule I controlled substances under U. S. federal law. These substances are illegal in many states and have not been approved by the U. S. Food and Drug Administration( FDA) for the treatment of any medical or mental health conditions. Content provided here does not imply endorsement and is intended solely for informational and educational purposes.
November 2025 13